Carter Gould
Stock Analyst at Barclays
(0)
# 3136
Out of 5,240 analysts
212
Total ratings
42.61%
Success rate
4.85%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Neurocrine Bioscienc... | Maintains: Overweight | 160 165 | 140.08 | 17.79% | 12 | Dec 23, 2024 | |
Gilead Sciences | Maintains: Equal-Weight | 84 95 | 91.91 | 3.36% | 14 | Nov 7, 2024 | |
Regeneron Pharmaceut... | Maintains: Overweight | 1080 1065 | 698.75 | 52.42% | 18 | Nov 1, 2024 | |
Travere Therapeutics | Maintains: Overweight | 18 20 | 17.7 | 12.99% | 6 | Nov 1, 2024 | |
Eli Lilly | Maintains: Overweight | 1025 975 | 752.59 | 29.55% | 11 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 190 180 | 145.32 | 23.86% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 42 43 | 56.27 | -23.58% | 14 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 142 140 | 100.32 | 39.55% | 10 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 300 315 | 270.74 | 16.35% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 200 212 | 172.33 | 23.02% | 14 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 100 | 74.72 | 33.83% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 3 | 1.33 | 125.56% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 32 | 26.54 | 20.57% | 14 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 3 | 0.98 | 206.12% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 3.04 | 196.05% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 95 | 47.28 | 100.93% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 25 20 | 31.59 | -36.69% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 73 | 64.52 | 13.14% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 0.89 | 12.36% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 110 172 | n/a | n/a | 7 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 12 | 1.7 | 605.88% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 2 | 0.89 | 68.54% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 15 | 0.03 | 49900% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 3 | 0.69 | 226.09% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 392 380 | 205.87 | 84.58% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 150 180 | n/a | n/a | 4 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 75 82 | 72.88 | 12.51% | 3 | Jan 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 183 188 | 419.49 | -55.18% | 1 | Jul 26, 2018 |